Vanessa Costhek Abílio in research grants and scholarships supported by FAPESP.
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Schizophrenia is a neuropsychiatric disorder that affects around 0.3% of the world population. Among its symptoms, there are evident alterations in hedonic processes, associated with both social impairments and increased substance consumption, suggesting the presence of a hedonic imbalance. This imbalance has been evaluated by our group in the schizophrenia model of the SHR strain. Simult…
The National Institute of Translational Medicine (NITM) was created in 2008 with the purpose of establishing a national network of research centers with outstanding experience in the investigation of biomarkers and new therapeutic targets and molecules in neuropsychiatric disorders, acting in the strategic area of Health and Medicines defined by the Federal Government. In the base of all …
Schizophrenia is a chronic and heterogeneous psychiatric condition caused by neurodevelopmental alterations. Its course, symptom manifestation, and response to antipsychotics differ between men and women, evidencing sexual dimorphism. Even with the medications currently used, their effects do not fully cover all symptoms of the disorder and induce significant adverse effects, leading appr…
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by deficits in the socio-communicative domain and the manifestation of restricted and repetitive behaviors and interests. ASD sociocommunicative deficits present sexual dimorphisms and are better masked in girls and women with the disorder. The main hypothesis that explains the sociocommunicative deficits in ASD…
Schizophrenia is a neuropsychiatric disorder affecting around 1% of the global population. Its main symptoms are positive, negative, and cognitive deficits. Among negative symptoms, alterations in hedonic behavior are evidenced and may vary between social stimulus and substance reward. We hypothesize a dysregulation of the hedonic tone, in which the abuse of substances might associate wit…
Schizophrenia is a debilitating mental disorder that affects 0.29% of the world's population. Despite having medications aimed at treating the symptoms of schizophrenia, such drugs induce serious adverse effects and are only effective in treating the positive symptoms of the disorder. For this reason, new therapeutic alternatives have been studied, with our group focusing on cannabinoid c…
Schizophrenia is a psychiatric disorder, characterized by positive, negative symptoms and cognitive deficits. Its incidence in the world population, in 2016, has already exceeded 21 million people. Changes in the central nervous system are related to this disorder, such as changes in the dopaminergic and glutamatergic systems. Schizophrenia is treated with antipsychotics, but these drugs …
Schizophrenia is a highly debilitating neuropsychiatric disorder. Current treatments are not effective to all the symptoms, are associated with sever side-effects and do not benefit all the patients. Therefore, the search for preventive strategies is crucial. Recently, we have verified that cannabidiol prevents the development of schizophrenia-like behavioral alterations in the poly I:C s…
(Only some records are available in English at this moment)
Changes on receptors, in the signaling cascade and / or expression of BDNF can not only result in a poor neural development, but also changes in neural plasticity and structural abnormalities that may be associated with the development of schizophrenia. Data obtained so far indicate a participation of BDNF in behaviors related to schizophrenia in our animal model, however, the techniques …
| 1 / 1 | Ongoing grants |
| 2 / 2 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 21 / 18 | Completed scholarships in Brazil |
| 1 / 1 | Completed scholarships abroad |
| 28 / 25 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID